On March 19th, Apeloa Pharmaceutical Co., LTD. (stock code: 000739) announced, The Company signs the License Agreement with MPP (the “Drug Patent Pool Organization”), MPP grants the Company non-exclusive, non-transferable, non-subcontracted, commercial and related rights for nematvir (nirmatrelvir) and nirmatrelvir / ritonavir) within the region (i. e., 95 LMICs countries, including India, Pakistan, Vietnam).
Based on the License Agreement, the Company will conduct the production of cooperative products at a production facility approved by the SRA (strict regulator) or prequalified by the WHO (World Health Organization).The cooperative products produced by the Company may be supplied to Pfizer and other MPP patents as required, and the Company may also purchase the required cooperative products from other MPP patent license assigns.
Pfizer’s Paxlovid is an oral small-molecule novel coronavirus treatment, a combination of two nematvir tablets and one ritonavir used to treat mild to moderate COVID-19 patients with a high risk of progression to severe illness.According to an interim analysis published by Pfizer in 2021, the Paxlovid has reduced the risk of hospitalization and death for high-risk COVID-19 patients by 89%.At present, several countries and regions worldwide have approved the Paxlovid emergency use authorization or temporary authorization.On February 11,2022, the drug was also approved by the China State Food and Drug Administration (NMPA).
The MPP license from Pfizer is a full recognition of Pfizer’s efficient technology research and development ability, high standard compliance ability and good cost control ability of Pro Pharmaceutical, and also builds a good platform for the company to continuously promote the internationalization strategy.In recent years, Apeloa pharmaceutical established the “technology creation, service health” enterprise mission, set up the “strong research and development, high standard compliance, low cost manufacturing” development concept, continue to increase r & d investment (in 2021, the company r & d investment reached 5.32% of the revenue), strengthen quality and EHS system, accelerate the construction of new capacity of projects, to build China’s technology pharmaceutical manufacturing leader, unremitting struggle to protect human health, contribute to the global disease resistance strength!
Post time: Mar-22-2022